The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

The latest research report published by Vantage Market Research, titled "An Increase in Demand and Opportunities for the ...

The cancer portfolio also put in a buoyant ... climbed 41 per cent to £101 million. The latter product will of course not have an impact on GSK's future growth, as it is one of the oncology ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.i The ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

Interactive Investor says the number of Isa millionaires has increased from 1,001 at the end of January 2024 to 1,607 by the ...

At Diageo, leadership is not just about titles it’s about impact, innovation, and inclusivity. As a global leader in the beverage industry, Diageo has long championed gender diversity, ensuring that ...

Versatope Therapeutics Incorporated, a biotechnology company developing vaccines and immuno-therapeutics announced today ...

The founders of Bugworks Research are attempting to bring to market a new class of antibiotics--a first in almost half a ...